MA32904B1 - Composes de purine - Google Patents

Composes de purine

Info

Publication number
MA32904B1
MA32904B1 MA33947A MA33947A MA32904B1 MA 32904 B1 MA32904 B1 MA 32904B1 MA 33947 A MA33947 A MA 33947A MA 33947 A MA33947 A MA 33947A MA 32904 B1 MA32904 B1 MA 32904B1
Authority
MA
Morocco
Prior art keywords
purine
compounds
pain
compound
formula
Prior art date
Application number
MA33947A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Charles Astles
Rossella Guidetti
Sean Patrick Hollinshead
Michael Wade Tidwell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA32904B1 publication Critical patent/MA32904B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention porte sur un composé de formule et sur des compositions pharmaceutiques pour le traitement de la douleur.
MA33947A 2008-12-18 2011-06-14 Composes de purine MA32904B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13858908P 2008-12-18 2008-12-18
PCT/US2009/067249 WO2010080306A1 (fr) 2008-12-18 2009-12-09 Composés purines

Publications (1)

Publication Number Publication Date
MA32904B1 true MA32904B1 (fr) 2011-12-01

Family

ID=41719189

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33947A MA32904B1 (fr) 2008-12-18 2011-06-14 Composes de purine

Country Status (29)

Country Link
US (1) US8252798B2 (fr)
EP (1) EP2379555B1 (fr)
JP (1) JP5559812B2 (fr)
KR (1) KR101319630B1 (fr)
CN (1) CN102256977B (fr)
AR (1) AR075104A1 (fr)
AU (1) AU2009335997B2 (fr)
BR (1) BRPI0923195A2 (fr)
CA (1) CA2746740C (fr)
CL (1) CL2011001464A1 (fr)
CO (1) CO6390101A2 (fr)
CR (1) CR20110340A (fr)
DO (1) DOP2011000196A (fr)
EA (1) EA018386B1 (fr)
EC (1) ECSP11011151A (fr)
ES (1) ES2536880T3 (fr)
HN (1) HN2011001700A (fr)
IL (1) IL213167A (fr)
MA (1) MA32904B1 (fr)
MX (1) MX2011006442A (fr)
NZ (1) NZ593088A (fr)
PA (1) PA8851501A1 (fr)
PE (1) PE20110999A1 (fr)
SG (1) SG172253A1 (fr)
TN (1) TN2011000291A1 (fr)
TW (1) TWI376378B (fr)
UA (1) UA104010C2 (fr)
WO (1) WO2010080306A1 (fr)
ZA (1) ZA201103943B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2923734B1 (fr) * 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Analogues de purines et leur utilisation en tant qu'agents immunosuppresseurs
EP2470508A1 (fr) 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Modulateurs des récepteurs de cannabinoïdes
US20130096104A1 (en) * 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
AR080711A1 (es) 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor
CN102803263B (zh) * 2010-03-31 2014-12-17 伊莱利利公司 用作cb2激动剂的嘌呤化合物
RU2013114352A (ru) 2010-09-15 2014-10-20 Ф. Хоффманн-Ля Рош Аг Азабензотиазолы, композиции и способы применения
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
JP5945554B2 (ja) 2011-02-25 2016-07-05 アリーナ ファーマシューティカルズ， インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター）
MX392150B (es) 2011-02-25 2025-03-21 Arena Pharm Inc Moduladores de receptores canabinoides.
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
BR112014006643A2 (pt) * 2011-09-20 2017-04-04 Hoffmann La Roche compostos de imidazopiridina, composições e métodos de uso dos mesmos
US9067943B2 (en) * 2011-11-25 2015-06-30 Hoffmann-La Roche Inc. [1,2,3]triazolo[4,5-D]pyrimidine derivatives
PE20151140A1 (es) * 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
BR112015027394A8 (pt) * 2013-05-02 2018-01-30 Hoffmann La Roche derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017052394A1 (fr) * 2015-09-23 2017-03-30 Uniwersytet Jagielloński Composés d'imidazopyridine et leur utilisation comme ligands du récepteur 5-ht6
WO2018137176A1 (fr) * 2017-01-25 2018-08-02 Eli Lilly And Company Traitement de la fibrose et de la stéatohépatite non alcoolique
WO2017181317A1 (fr) * 2016-04-18 2017-10-26 Eli Lilly And Company Traitement de la stéatohépatite non alcoolique et de la fibrose
WO2017184412A1 (fr) 2016-04-18 2017-10-26 Eli Lilly And Company Agoniste cannabinoïde de la purine pour traiter la stéatohépatite non alcoolique et la fibrose
EP3558996A4 (fr) * 2016-12-21 2020-08-05 Research Triangle Institute, International Dérivés de diarylpurine présentant une biodisponibilité améliorée
US20200078358A1 (en) 2017-05-08 2020-03-12 Arena Pharmaceuticals, Inc. Compounds and Methods for Treatment of Visceral Pain
WO2024017227A1 (fr) * 2022-07-21 2024-01-25 长春金赛药业有限责任公司 Composé récepteur cannabinoïde à noyau fusionné substitué et son utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
WO2003022214A2 (fr) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Composes a base de piperazine et d'homopiperazine
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050153989A1 (en) 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CN101044143A (zh) * 2004-10-22 2007-09-26 辉瑞产品公司 制备嘌呤化合物的方法
WO2006128172A2 (fr) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Procede pour traiter des troubles auto-immuns regules par des lymphocytes b
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
JP2013512245A (ja) * 2009-11-24 2013-04-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 脂肪酸合成酵素阻害剤としてのアザベンズイミダゾール
AR080711A1 (es) * 2010-03-31 2012-05-02 Lilly Co Eli Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor

Also Published As

Publication number Publication date
CA2746740C (fr) 2014-01-14
PA8851501A1 (es) 2010-07-27
NZ593088A (en) 2012-12-21
US8252798B2 (en) 2012-08-28
ECSP11011151A (es) 2011-07-29
US20100160288A1 (en) 2010-06-24
TW201024296A (en) 2010-07-01
WO2010080306A1 (fr) 2010-07-15
AU2009335997A1 (en) 2011-06-23
IL213167A0 (en) 2011-07-31
CA2746740A1 (fr) 2010-07-15
CR20110340A (es) 2011-09-16
HN2011001700A (es) 2013-05-06
ES2536880T3 (es) 2015-05-29
SG172253A1 (en) 2011-07-28
EA201170832A1 (ru) 2011-12-30
EP2379555A1 (fr) 2011-10-26
DOP2011000196A (es) 2011-10-31
CO6390101A2 (es) 2012-02-29
MX2011006442A (es) 2011-07-19
UA104010C2 (en) 2013-12-25
KR101319630B1 (ko) 2013-10-17
AU2009335997B2 (en) 2012-05-10
TN2011000291A1 (en) 2012-12-17
BRPI0923195A2 (pt) 2016-02-16
KR20110084459A (ko) 2011-07-22
PE20110999A1 (es) 2012-01-16
IL213167A (en) 2013-11-28
AR075104A1 (es) 2011-03-09
ZA201103943B (en) 2012-11-28
TWI376378B (en) 2012-11-11
EA018386B1 (ru) 2013-07-30
CL2011001464A1 (es) 2012-01-20
EP2379555B1 (fr) 2015-02-25
JP5559812B2 (ja) 2014-07-23
CN102256977A (zh) 2011-11-23
CN102256977B (zh) 2014-04-16
JP2012512873A (ja) 2012-06-07

Similar Documents

Publication Publication Date Title
TN2011000291A1 (en) Purine compounds
EP2450046A4 (fr) Composition à visée médicale pour le traitement de la bronchite et sa préparation
MA32171B1 (fr) Compose heterocyclique
EP2174667A4 (fr) Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
MA33909B1 (fr) Pyrrolidinones accoles en tant d'inhibiteurs de syk
SI2150530T1 (sl) Substituirani sulfonamidni derivati
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA33428B1 (fr) Agonistes du gpr119
EP2528603A4 (fr) Compositions pharmaceutiques pour le traitement de la douleur et d'autres indications
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
UY31065A1 (es) Heterociclos ciclicos
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EP2331520A4 (fr) Dérivés de rosamine comme agents pour le traitement d'un cancer
EP2312946A4 (fr) Dérivés de pyrimidine pour le traitement de la maladie d alzheimer
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EP2173364A4 (fr) Traitement ou prévention d'une infection par un rotavirus
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
EP2269996A4 (fr) Composition médicinale contenant un composé de benzo[a]phénoxanthine comme principe actif pour la prévention ou le traitement de maladie protozoaire
DE602007007934D1 (en) Imidazoazephinonverbindungen
EP2331092A4 (fr) Procédés et compositions pour l'administration de 3-halopyruvate et de composés associés pour le traitement du cancer
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.